Nov. 12 at 12:14 PM
$ZBIO $35.20 +2.73
Holding long position
Original BUY at
$7.55 (2.4.25).
https://stocktwits.com/G101SPM/message/631438005
CHANGE EXIT TO
$45.00 FROM
$32.00.
KEY FACTS:
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -
- Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) -
- Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor in Phase 3 development for progressive forms of Multiple Sclerosis (MS) -
- Entered into obexelimab funding agreement with Royalty Pharma for up to
$300.0 million, including
$75M upfront, to support clinical development and potential commercial launch -
